Detalhe da pesquisa
1.
Anxiety and dysautonomia symptoms in patients with a NaV1.7 mutation and the potential benefits of low-dose short-acting guanfacine.
Clin Auton Res
; 34(1): 191-201, 2024 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-38064009